# Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

> **NCT05785715** · PHASE2 · TERMINATED · sponsor: **AbbVie** · enrollment: 81 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** NX-13 250mg
- **DRUG:** NX-13 750mg
- **DRUG:** NX-13 Placebo

## Key facts

- **NCT ID:** NCT05785715
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-24
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** Sponsor Decision\_Not Safety Related
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05785715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05785715, "Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05785715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*